Bile Duct Neoplasms Clinical Trial
— MBOPOfficial title:
SAFETY AND EFFICACY OF INTRA DUCTAL RADIO FREQUENCY ABLATION IN UNRESECTABLE MALIGNANT BILIARY OBSTRUCTION: PROSPECTIVE OBSERVATIONAL STUDY
NCT number | NCT05320328 |
Other study ID # | RFA |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | June 10, 2021 |
Est. completion date | December 10, 2022 |
Endoscopic retrograde cholangio pancreatography procedure will performed as per local standard procedure.After common bile duct cannulation,cholangiography will be performed (to confirm the stricture) followed by biliary sphincterotomy. All biliary strictures(Bismuth Type I/II/III/IV) will be enrolled for the study. Patient opting for Uncovered self expandable metallic stent / Plastic stent will undergo biliary stent placement and considered under control arm Patient opting for radio frequency ablation + Uncovered SEMS/Plastic stent will undergo radio frequency ablation and biliary stent placement and considered under Study arm The RFA probe will be inserted into the bile duct alongwith the guidewire. Keeping the electrode overlapping the stricture, RFA will be performed using a power of 10W for 120 seconds. The electrode will be kept at the ablation site for an additional 1 minute to allow the RFA probe to cool before removal to prevent thermal injury of normal tissue and/or endoscope accessory channel. If the stricture is more than 3 cm, step-by-step RFA will be performed from the superior to inferior aspect. After RFA application, an uncovered SEMS/Plastic stent will be placed.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | December 10, 2022 |
Est. primary completion date | June 10, 2022 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Age 18-75 years 2. Malignant biliary obstruction confirmed using computed tomography (CT) or abdominal magnetic resonance imaging(MRI), with pathological confirmation whenever possible; 3. Clinical jaundice, a serum bilirubin level greater than 5 mg/dL, and/or cholangitis; 4. ECOG performance status score=2 5. Un resectability or refusal to be surgically treated. 6. Eligible patients were those with biliary obstruction due to cancer of the gallbladder, or bile ducts; who were considered unsuitable for surgery because of distant metastases, vascular invasion, or severe disability due to age or associated diseases. 7. Non-resectability was established through the consensus opinion of a multidisciplinary tumor board. 8. Written informed consent signed by the patient. Exclusion Criteria: |
Country | Name | City | State |
---|---|---|---|
India | Asian Institute of Gastroenterology | Hyderabad | Telangana |
Lead Sponsor | Collaborator |
---|---|
Asian Institute of Gastroenterology, India |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prospectively evaluate the safety and efficacy of combining intraductal Radio frequency ablation with biliary metal/ plastic stent placement for patients with malignant biliary obstruction. | satety of radio frequency ablation assessed by complications/adverse effects post procedure and efficacy of the procedure will be assessed by stent patency at the end of one month | 12 months | |
Secondary | Stent patency at 1 year | Stent patency will be estimated by bio chemical parameters (Total bilirubin, Alkaline phosphatase) or ultra sound abdomen scan | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05600803 -
Screening Single-operator Cholangioscopy for Neoplastic Bile Duct Lesions
|
||
Recruiting |
NCT05286814 -
M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
Recruiting |
NCT06115655 -
A Single-center, Prospective Cohort Study on the Differentiation of Benign and Malignant Bile Duct Stenosis Based on Bile and Peripheral Blood cfDNA Methylation Profiles
|
||
Enrolling by invitation |
NCT03951324 -
Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study
|
||
Active, not recruiting |
NCT05374122 -
AI Guidance for Biopsy in Suspected Cholangiocarcinoma
|
N/A | |
Terminated |
NCT04276090 -
Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma
|
N/A | |
Completed |
NCT01232101 -
Covered or Uncovered Bile Duct Stents
|
N/A | |
Active, not recruiting |
NCT00582647 -
Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract
|
||
Recruiting |
NCT00915863 -
Evaluation of Isolated Roux-en-Y Reconstruction After Pancreaticoduodenectomy
|
N/A | |
Recruiting |
NCT05172310 -
PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI
|
Phase 1 | |
Completed |
NCT01845337 -
Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine
|
Phase 2 | |
Completed |
NCT04847167 -
Mechanistic Loop Resolution Strategy for Short-type Single Balloon Enteroscopy
|
N/A | |
Completed |
NCT00634751 -
CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03838913 -
Whole-Exome Sequencing (WES) of Intraductal Neoplasms of the Bile Duct (IPNB)
|